Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (10)	1/9/1999 4:44:00 PM
From: William Whitehead Jr.	Read Replies (1) \| Respond to of 423

Congradulations to all on such an informative and well documented web site. Biotech's (and related) are near and dear to my heart - they comprise over 75% of my portfolio. I did close to 5 years of pre-med sciences at the U of T and while I may understand a lot of the science involved, I can't explain why so many are trading at such deep discounts to their actual cash value of near term projected revenue stream. A few that I'm holding are: (in no necessary order of importance): Salix Pharm. (TSE:SLX), Biotech Holdings (ASE:BIO), Inex Pharm. (TSE:IEX), Ceapro (ASE:CZO), Hyal Pharm (TSE:HPC), Biomira (TSE:BRA), Briana Biotech (VSE:BIA) ... and so on! Reading the last few posts has provided insight into possibly others. If I can help/share what I know please let me know. Whitey,

To: BRAVEHEART who wrote (10)	1/12/1999 8:38:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 423

LXR UPDATE: Hi Gang, Since my post on the 6th there have been two releases relative to LXR & their strategy as it unfolds. I expect many more of these over the next several months. LXR Biotechnology Inc. and RPR Gencell Collaborate on SARP biz.yahoo.com Key Excerpt: ''SARPs regulate fundamental processes in the life/death cycle of cells and thereby have great potential as therapeutics,'' commented Paul J. Hastings, President and CEO of LXR. ''We are pleased that a company of the stature of Rhone-Poulenc Rorer has recognized the potential of SARPs. This collaboration is one of several that LXR plans to establish for the development of SARP technology for a number of diseases,'' added Mr. Hastings. This should result in some interesting collaborations leading up to the partnering of the three major products. Good to see Big Pharma want's to establish ties. & biz.yahoo.com Key Excerpt: "Dr. Topol has served as principal investigator for more than 15 international multi-center clinical trials including trials that led to the approval of TPA (Genentech: Activase), a compound used to dissolve blood clots causing heart attack, and abciximab (Centocor and Eli Lilly: ReoPro), a compound used to prevent clot reformation in connection with treatment of heart attack. Activase and ReoPro are two of the most important cardiology drugs developed by the biotechnology industry." "Dr. Topol's primary focus on LXR's Cardiovascular Clinical Development Board will be to advise the Company on the preclinical and clinical development of Elirex™ and related compounds such as LXR1035, the Company's proprietary compounds for the protection of heart muscle cells in heart attack." Technically we did not see much from this second release primarily because of the indicators... : ( In fact rarely does the addition of a new face result in any dramatic responses unless they are buz name people. However I believe it is still a considerable development which will benefit shareholders long term. These two releases suggest LXR will continue a R&D presence ( through joint collaborations ) as it changes over to a product development strategy. BEST WISHES LONE WOLF